Related Experiment Video
Updated: Aug 22, 2025

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a
James S H Wong1,2, Sarah Masson1, Alan Huang1
1Correctional Health Services, BC Mental Health and Substance Use Services, Provincial Health Services Authority, British Columbia, Canada.
Abstract:
Incarcerated clients experience high rates of opioid use disorder and overdose. It is critical that opioid agonist treatment (OAT) is provided in correctional facilities. However, few receive OAT due to concerns about diversion, misuse, and safety. Buprenorphine extended-release (BUP-XR), a monthly buprenorphine depot injection, could be especially advantageous in the correctional setting as it can prevent diversion and misuse, saving staff resources and time. An injection of BUP-XR is costly compared with a monthly supply of buprenorphine/naloxone (BUP/NX) tablets. We demonstrate that when factoring in the added costs of medication preparation, administration, monitoring, and personnel, it is more economical to provide BUP-XR than BUP/NX. Other facilities, by utilizing our cost breakdown, can determine whether BUP-XR is economically advantageous at their own facility.
More Related Videos
04:13Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Delivery: Enteral Route
Opioid Analgesics: Morphine and Other Natural Cogeners